Institutional shares held 47.9 Million
202K calls
110K puts
Total value of holdings $114M
$479K calls
$261K puts
Market Cap $69.1M
29,014,000 Shares Out.
Institutional ownership 165.02%
# of Institutions 126


Latest Institutional Activity in CABA

Top Purchases

Q3 2024
Fred Alger Management, LLC Shares Held: 4.12M ($9.8M)
Q3 2024
Bain Capital Life Sciences Investors, LLC Shares Held: 2.76M ($6.57M)
Q3 2024
Millennium Management LLC Shares Held: 1.63M ($3.88M)
Q3 2024
Point72 Asset Management, L.P. Shares Held: 667K ($1.59M)
Q3 2024
Cubist Systematic Strategies, LLC Shares Held: 573K ($1.36M)

Top Sells

Q3 2024
State Street Corp Shares Held: 896K ($2.13M)
Q3 2024
Jpmorgan Chase & CO Shares Held: 280K ($666K)
Q3 2024
Citadel Advisors LLC Shares Held: 4.51K ($10.7K)
Q3 2024
T. Rowe Price Investment Management, Inc. Shares Held: 3.67M ($8.74M)
Q3 2024
Squarepoint Ops LLC Shares Held: 157K ($374K)

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.


Insider Transactions at CABA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
11K Shares
From 1 Insiders
Exercise of conversion of derivative security 11K shares
Sell / Disposition
11K Shares
From 1 Insiders
Open market or private sale 11K shares

Track Institutional and Insider Activities on CABA

Follow Cabaletta Bio, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CABA shares.

Notify only if

Insider Trading

Get notified when an Cabaletta Bio, Inc. insider buys or sells CABA shares.

Notify only if

News

Receive news related to Cabaletta Bio, Inc.

Track Activities on CABA